A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.

Using the overall median value (0.41% across arms) to stratify patients, >0.41% of CD8+ CD137+ T-cell density within TLAs correlated with improved disease-free survival (DFS) (HR 0.30, 95% confidence interval [CI] 0.11,0.86, p = 0.026) (Supplementary Table 1 , Supplementary Figure 2 ) but did not reach statistical significance with OS (HR 0.61 [95% CI 0.22,1.70], p = 0.349) (Supplementary Table 1 , Supplementary Figure 2 ).

also in 111,027 other papers